190 related articles for article (PubMed ID: 38893123)
1. Checkpoint Inhibitors in Dogs: Are We There Yet?
Giuliano A; Pimentel PAB; Horta RS
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893123
[TBL] [Abstract][Full Text] [Related]
2. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.
Zabeti Touchaei A; Vahidi S
Cancer Cell Int; 2024 Mar; 24(1):102. PubMed ID: 38462628
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
Mortezaee K; Majidpoor J
Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
[TBL] [Abstract][Full Text] [Related]
9. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Kuske M; Haist M; Jung T; Grabbe S; Bros M
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406483
[TBL] [Abstract][Full Text] [Related]
11. Anticancer natural products targeting immune checkpoint protein network.
Chun KS; Kim DH; Raut PK; Surh YJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Jo W; Won T; Daoud A; Čiháková D
Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
[TBL] [Abstract][Full Text] [Related]
16. Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer.
Islam MK; Stanslas J
Pharmacol Ther; 2021 Nov; 227():107870. PubMed ID: 33895183
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
18. Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.
Pandey P; Khan F; Qari HA; Upadhyay TK; Alkhateeb AF; Oves M
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337133
[TBL] [Abstract][Full Text] [Related]
19. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells.
Mortezaee K; Majidpoor J
Heliyon; 2023 Dec; 9(12):e23171. PubMed ID: 38144305
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
